GENOVA (9341) Fundamentals 2026 — P/E 38.8x, Revenue Analysis | SniperIQ
GENOVA (9341) is a JP-listed Healthcare company in Medical - Healthcare Information Services with a market capitalization of ¥10.7B, trading at ¥616.00 on the JPX. This SniperIQ fundamentals page covers GENOVA's valuation (P/E 38.8x, P/B 1.5x), profitability (net margin 2.4%), revenue (¥11.6B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is GENOVA's market cap?
GENOVA (9341) has a market capitalization of approximately ¥10.7B, trading at ¥616.00 on the JPX. Market cap moves with the live share price.
What is GENOVA's P/E ratio?
GENOVA's trailing twelve-month P/E ratio is 38.8x, with a price-to-book (P/B) of 1.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is GENOVA?
GENOVA runs a net profit margin of 2.4%, a gross margin of 55.9%, and an operating margin of 3.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does GENOVA generate?
GENOVA reported revenue of ¥11.6B for fiscal year 2025, with net income of ¥275M and earnings per share (EPS) of 15.9. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does GENOVA pay a dividend?
GENOVA offers a trailing dividend yield of about 4.9%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is GENOVA financially healthy?
GENOVA carries a debt-to-equity ratio of 0.11x and a current ratio of 3.73x, with a market beta of -0.14. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is GENOVA a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For GENOVA (9341) the key facts are: market cap ¥10.7B, P/E 38.8x, revenue ¥11.6B, 52-week range 541-752. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track GENOVA's full fundamentals live
Get GENOVA's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.